AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for AIkido Pharma Inc. (AIKI)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
a week ago | PRNewsWire
2 weeks ago | PRNewsWire
a month ago | PRNewsWire
a month ago | PRNewsWire
a month ago | PRNewsWire
2 months ago | PRNewsWire
2 months ago | Newsfile Corp
2 months ago | PRNewsWire
2 months ago | Newsfile Corp
3 months ago | Newsfile Corp